GSK, Google parent forge £540m bioelectronic medicines firm
Tie-up will develop miniaturised, implantable devices that can modify electrical nerve signals
London
GLAXOSMITHKLINE (GSK) and Google parent Alphabet's life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a novel field of medicine called bioelectronics.The tie-up shows the growing convergence of health care and technology.
Verily Life Sciences - known as Google's life sciences unit until last year - and Britain's biggest drugmaker will together contribute £540 million (S$953.9 million) over seven years to Galvani Bioelectronics, they said on Monday.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Technology
Meta’s results are best viewed through rose-tinted AI glasses
'Harvesting data': Latin American AI startups transform farming
After long peace, Big Tech faces US antitrust reckoning
Tech’s cash crunch sees creditors turn ‘violent’ with one another
Tech millionaires chase billionaire tax shields with ‘swap fund’
Elon Musk’s Starlink profits are more elusive than investors think